VASCONCELLES MICHAEL — SEC Form 4 filings
SEC reporting owner CIK 1734755. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-04.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-05 to 2026-06-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 2,728 shares, $31,647 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 2,728 shares @ $11.60 ($31,647) in Day One Biopharmaceuticals, Inc., filed 2026-02-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) | Head of Research and Dev. | 4 | — | 1 leg · 2,728 sh · $31,647 | 11 |
| ImmunoGen, Inc. (IMGN) | EVP R&D & MEDICAL AFFAIRS | 2 | — | — | 4 |
| Kura Oncology, Inc. (KURA) | Director | 3 | — | — | 4 |
Form 4 filings — VASCONCELLES MICHAEL
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to issuer (D): 4,397 · Disposition to issuer (D): 346,000 (derivative) · Disposition to issuer (D): 171,000 (derivative) · Disposition to issuer (D): 226,000 (derivative) · Disposition to issuer (D): 106,875 (derivative) | EDGAR |
| 2026-02-18 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Option exercise (M): 7,125 · Sale (S): 2,728 @ $11.60 · Option exercise (M): 7,125 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 171,000 (derivative) @ $0 · Grant/award (A): 114,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 346,000 (derivative) @ $0 · Grant/award (A): 226,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 52,000 (derivative) @ $0 · Grant/award (A): 17,333 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | ImmunoGen, Inc. (IMGN) | Disposition to issuer (D): 1,327 · Disposition to issuer (D): 960,000 (derivative) · Disposition to issuer (D): 50,515 (derivative) | EDGAR |
| 2024-02-05 | 4 | ImmunoGen, Inc. (IMGN) | Grant/award (A): 50,515 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1734755 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →